Shares of Biogen Inc. BIIB slid 2.56% to $146.79 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.95% to 5,872.16 and Dow ...
This move diversifies options for patients following the earlier approval of Eisai and Biogen's Leqembi in January. CVS faces ...
Reuters on MSN9h
Eli Lilly's Alzheimer's treatment approved in China(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend ...
(Corrects paragraph 8 of Dec. 17 story to reflect that the EU regulator reversed its July decision in November to recommend ...
We will explore the elements of innovation ecosystems and offer insights into how entrepreneurs can leverage them for success ...
The Centers for Medicare and Medicaid Services is directing all Medicare Advantage plans to cover Qalsody for treating ...
China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...
Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback